Premenstrual Syndrome Treatment Market Size, Share, Trends, Growth and Forecast 2032

Premenstrual Syndrome Treatment Industry Prospective:

The global premenstrual syndrome treatment market size was evaluated at $2 billion in 2023 and is slated to hit $3 billion by the end of 2032 with a CAGR of nearly 4% between 2024 and 2032.

Request Free Sample

Premenstrual Syndrome Treatment Market: Overview

Premenstrual syndrome is a common condition causing physical, behavioral, and emotional changes occurring in the luteal phase of the menstrual cycle. Symptoms can differ from woman to woman and treatment can vary based upon the symptoms. A few of the common treatments for premenstrual syndrome include lifestyle changes, over-the-counter medications, hormonal treatments, prescribed medicines, and alternative treatments. Making lifestyle changes, such as doing physical exercise and intake of nutritious diet, are some of the effective treatments for premenstrual syndrome in women.

Key Insights

• As per the analysis shared by our research analyst, the global premenstrual syndrome treatment market is projected to expand annually at the annual growth rate of around 4% over the forecast timespan (2024-2032)
• In terms of revenue, the global premenstrual syndrome treatment market size was evaluated at nearly $2 billion in 2023 and is expected to reach $3 billion by 2032.
• The global premenstrual syndrome treatment market is anticipated to grow rapidly over the forecast timeline owing to surging awareness about premenstrual syndrome and the drafting of government programs creating awareness about the same.
• In terms of treatment type, the lifestyle modifications segment is slated to dominate the segmental space over the forecast period.
• Based on distribution channel, the pharmacies segment is predicted to lead the global industry surge in the ensuing years.
• Region-wise, the Asia-Pacific premenstrual syndrome treatment industry is projected to register the fastest CAGR during the assessment timespan.

Premenstrual Syndrome Treatment Market: Growth Factors

Escalating incidences of premenstrual syndrome across the globe to embellish the growth of the market globally

Rising occurrence of premenstrual syndrome in women is likely to boost the growth of the global premenstrual syndrome treatment market. Surging awareness about premenstrual syndrome and drafting government programs creating awareness about the same will drive the global market trends.

Huge focus on improving women’s health and breakthroughs in medical treatments such as hormone therapies, analgesics, and anti-depressants will steer the global market expansion. Aging population prone to the disease will augment the global market trends.

Premenstrual Syndrome Treatment Market: Restraints

Lesser knowhow among the female population about premenstrual syndrome to constrict the global industry surge

Lack of awareness among women about premenstrual syndrome symptoms can severely impact the expansion of the global premenstrual syndrome treatment industry. Furthermore, lesser treatment alternative availability can impact the growth rate of the global industry. Adverse effects of current treatment can degrade the global industry upsurge in the years ahead.

Premenstrual Syndrome Treatment Market: Opportunities

Surging patient inclination towards non-pharmacological therapies to craft panoramas of opportunities for the global market

Breakthroughs in pharmacological treatments and a rise in research activities are expected to open new growth avenues for the global premenstrual syndrome treatment market. Furthermore, growing patient preference for non-pharmacological treatment, such as intake of healthy food and adoption of cognitive behavioral therapy, will spearhead the global market surge in the years ahead.

Premenstrual Syndrome Treatment Market: Challenges

Rising healthcare costs & inadequate compensation policies can challenge the global industry progress

Surging healthcare prices and less insurance coverage can retard access to premenstrual syndrome treatment, thereby challenging the growth of the global premenstrual syndrome treatment industry. Cultural stigmas pertaining to menstruation can decline the growth of the industry across the globe.

Premenstrual Syndrome Treatment Market: Report Scope

Premenstrual Syndrome Treatment Market: Segmentation

The global premenstrual syndrome treatment market is divided into treatment type, distribution channel, and region.              

In terms of treatment type, the premenstrual syndrome treatment market across the globe is segmented into pharmaceutical medications, complementary & alternative therapies, lifestyle modifications, and over-the-counter medications segments. The lifestyle modifications segment is likely to be the dominating segment during the forecast timeline owing to its low cost, non-invasive features, and minimum side effects.

On the basis of distribution channel, the global premenstrual syndrome treatment industry is bifurcated into direct-to-consumer, pharmacies, and hospitals & clinics segments. Furthermore, the pharmacies segment is predicted to lead the growth of the global industry in the coming eight years. The key growth drivers of the segment are easy access to medicines, guidance, and counseling to patients in pharmacies. Moreover, easy access to medicines in pharmacies is due to the availability of a strong distribution network of pharmacies.

Premenstrual Syndrome Treatment Market: Regional Insights

North America is projected to maintain a leading position in the global market over the analysis timeline

North America, which accounted for approximately 52% of the global premenstrual syndrome treatment market revenue in 2023, is expected to maintain number one status in the period from 2024 to 2032. Apparently, a burgeoning growth of the market in North America over the forecast period can be due to the rising occurrence of premenstrual syndrome in North American women along with the presence of key players in countries such as the U.S.

Apart from this, the presence of advanced healthcare amenities in the region will enhance the revenue growth of the market in North America. The region has giant players in biopharmaceutical and biomedical research, thereby driving the innovation in premenstrual syndrome treatment, and thereby creating lucrative growth opportunities for the market in the North American region.

Asia-Pacific premenstrual syndrome treatment industry is set to record the highest CAGR in the forecast period. The industry expansion in APAC can be attributed to the surging women population in countries such as India, Bangladesh, Pakistan, and China. Demand for advanced healthcare services and an increase in the per capita income in Asia will propel the expansion of the industry in APAC.     

Premenstrual Syndrome Treatment Market: Competitive Space

The global premenstrual syndrome treatment market profiles key players such as:

• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• MetP Pharma AG
• GlaxoSmithKline
• Eli Lilly and Company
• Novartis International AG
• Asarina Pharma AB
• Merck
• Bayer AG
• Mylan N.V.
• Pherin Pharmaceuticals
• Umecrine Mood AB
• Chattem Inc.
• H. Lundbeck A/S

The global premenstrual syndrome treatment market is segmented as follows:

By Treatment Type

• Pharmaceutical Medications
• Complementary & Alternative Therapies
• Lifestyle Modifications
• Over-the-Counter Medications

By Distribution Channel

• Direct-To-Consumer
• Pharmacies
• Hospitals & Clinics

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa